JP5669748B2 - １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩 - Google Patents

１１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩 Download PDF

Info

Publication number
JP5669748B2
JP5669748B2 JP2011540664A JP2011540664A JP5669748B2 JP 5669748 B2 JP5669748 B2 JP 5669748B2 JP 2011540664 A JP2011540664 A JP 2011540664A JP 2011540664 A JP2011540664 A JP 2011540664A JP 5669748 B2 JP5669748 B2 JP 5669748B2
Authority
JP
Japan
Prior art keywords
batch
citrate
ray diffraction
salt
shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011540664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511571A (ja
JP2012511571A5 (cg-RX-API-DMAC7.html
Inventor
ダイモック，ブライアン
リー，チェン・シャ・アンジェリン
ウィリアム，アンソニー・デオドーニア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI Biopharma Corp filed Critical CTI Biopharma Corp
Publication of JP2012511571A publication Critical patent/JP2012511571A/ja
Publication of JP2012511571A5 publication Critical patent/JP2012511571A5/ja
Application granted granted Critical
Publication of JP5669748B2 publication Critical patent/JP5669748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2011540664A 2008-12-11 2009-12-09 １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩 Active JP5669748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121,668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (3)

Publication Number Publication Date
JP2012511571A JP2012511571A (ja) 2012-05-24
JP2012511571A5 JP2012511571A5 (cg-RX-API-DMAC7.html) 2013-01-24
JP5669748B2 true JP5669748B2 (ja) 2015-02-12

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540664A Active JP5669748B2 (ja) 2008-12-11 2009-12-09 １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩

Country Status (23)

Country Link
US (2) US8980873B2 (cg-RX-API-DMAC7.html)
EP (1) EP2376499B1 (cg-RX-API-DMAC7.html)
JP (1) JP5669748B2 (cg-RX-API-DMAC7.html)
KR (1) KR101729918B1 (cg-RX-API-DMAC7.html)
CN (1) CN102282148B (cg-RX-API-DMAC7.html)
AR (2) AR074724A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009325147B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922736B1 (cg-RX-API-DMAC7.html)
CA (1) CA2746058C (cg-RX-API-DMAC7.html)
DK (1) DK2376499T3 (cg-RX-API-DMAC7.html)
ES (1) ES2536558T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150428T1 (cg-RX-API-DMAC7.html)
IL (3) IL213418A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011006206A (cg-RX-API-DMAC7.html)
MY (1) MY160005A (cg-RX-API-DMAC7.html)
NZ (1) NZ593223A (cg-RX-API-DMAC7.html)
PL (1) PL2376499T3 (cg-RX-API-DMAC7.html)
PT (1) PT2376499E (cg-RX-API-DMAC7.html)
RU (1) RU2527970C2 (cg-RX-API-DMAC7.html)
SG (1) SG171907A1 (cg-RX-API-DMAC7.html)
TW (1) TWI449705B (cg-RX-API-DMAC7.html)
WO (1) WO2010068181A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104032B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376499B1 (en) 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
ES2536276T3 (es) * 2008-12-11 2015-05-22 Cti Biopharma Corp. Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
DE60205888T2 (de) * 2001-05-14 2006-07-06 Pfizer Products Inc., Groton Das citratsalz von 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaen
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE60209929T2 (de) * 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
WO2007058628A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
EP2376499B1 (en) 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Also Published As

Publication number Publication date
RU2527970C2 (ru) 2014-09-10
AU2009325147B2 (en) 2014-08-14
CN102282148A (zh) 2011-12-14
WO2010068181A8 (en) 2011-08-18
IL289379A (en) 2022-02-01
ZA201104032B (en) 2012-08-29
KR20110106344A (ko) 2011-09-28
EP2376499B1 (en) 2015-02-25
SG171907A1 (en) 2011-07-28
NZ593223A (en) 2013-08-30
BRPI0922736A8 (pt) 2021-11-09
US20110294831A1 (en) 2011-12-01
JP2012511571A (ja) 2012-05-24
CN102282148B (zh) 2014-12-24
IL250310A0 (en) 2017-03-30
TWI449705B (zh) 2014-08-21
PL2376499T3 (pl) 2015-07-31
US8980873B2 (en) 2015-03-17
HRP20150428T1 (xx) 2015-06-19
EP2376499A1 (en) 2011-10-19
DK2376499T3 (en) 2015-05-04
WO2010068181A1 (en) 2010-06-17
KR101729918B1 (ko) 2017-04-25
RU2011126173A (ru) 2013-01-20
BRPI0922736B1 (pt) 2022-02-22
US20150322084A1 (en) 2015-11-12
TW201028426A (en) 2010-08-01
AR074724A1 (es) 2011-02-09
BRPI0922736A2 (pt) 2017-10-31
MX2011006206A (es) 2011-07-20
US9624242B2 (en) 2017-04-18
HK1161877A1 (en) 2012-08-10
ES2536558T3 (es) 2015-05-26
MY160005A (en) 2017-02-15
AR114133A2 (es) 2020-07-22
AU2009325147A1 (en) 2011-06-23
IL213418A0 (en) 2011-07-31
PT2376499E (pt) 2015-06-03
CA2746058A1 (en) 2010-06-17
CA2746058C (en) 2016-05-17

Similar Documents

Publication Publication Date Title
JP6114849B2 (ja) プリン誘導体の結晶性形態
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
JP5669748B2 (ja) １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩
TWI457342B (zh) １１－（２－吡咯啶－１－基－乙氧基）－１４，１９－二－５，７，２６－三氮雜－四環〔１９．３．１．１（２，６）．１（８，１２）〕二十七碳－１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３－十烯順丁烯二酸鹽
CN102762577B (zh) 9e-15-(2-吡咯烷-1-基-乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂-四环[18.3.1.1(2,5).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯柠檬酸盐
CN118388481A (zh) 用于制备fgfr抑制剂的方法
CN117157294A (zh) 作为蛋白激酶抑制剂的杂环化合物的结晶形式
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141216

R150 Certificate of patent or registration of utility model

Ref document number: 5669748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250